Patent
Composition for bone regeneration
| العنوان: | Composition for bone regeneration |
|---|---|
| Patent Number: | 11577,005 |
| تاريخ النشر: | February 14, 2023 |
| Appl. No: | 15/757207 |
| Application Filed: | September 14, 2015 |
| مستخلص: | The composition for bone regeneration, comprises a) a first phase (3) comprising a plurality of cross-linked hydrogel chunks (1) having a mean diameter of less than 1000 μm and incorporating an amount of mineral particles (2); and b) a second phase (4) comprising a physiologically-compatible aqueous liquid acting as a carrier for the chunks; the chunks being embedded in the second phase (4). The mineral particles (2) have a mean diameter of less than 10 μm and the amount of the mineral particles (2) is less than 20 weight-% of the first phase. |
| Inventors: | École Polytechnique Fédérale de Lausanne (EPFL) (Lausanne, CH) |
| Assignees: | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (Lausanne, CH) |
| Claim: | 1. A composition comprising: a) a gel phase as a first phase comprising a plurality of cross-linked hydrogel chunks having a mean diameter of less than 1000 μm and wherein an amount of mineral particles are incorporated in said cross-linked hydrogel chunks; and b) an aqueous phase as a second phase comprising a physiologically-compatible aqueous liquid that acts as a carrier for the chunks, the chunks being embedded in the second phase; wherein: the mineral particles have a mean diameter of less than 10 μm; and the amount of the mineral particles is less than 20 weight-% of the first phase; and wherein the composition is formulated as an injectable composition for bone regeneration. |
| Claim: | 2. The composition according to claim 1 , wherein the mineral particles have a mean diameter of less than 5 μm. |
| Claim: | 3. The composition according to claim 1 , wherein the second phase further comprises nano- to micro-sized calcium phosphate particles selected from the group consisting of calcium pyrophosphate, calcium carbonate, monocalcium phosphate monohydrate, monocalcium phosphate, anhydrous dicalcium phosphate, dicalcium phosphate dihydrate, octocalcium phosphate, alpha-tricalcium phosphate, beta-tricalcium phosphate, hydroxyapatite, tetracalcium phosphate, calcium-deficient hydroxyapatite, fluoroapatite, amorphous calcium phosphate and oxyapatite, wherein one or more substances are loaded on a surface of the mineral particles, said one or more substances being selected from the group consisting of: a) drugs, bioactive molecules, anabolic bone active substances, anti-catabolic bone active substances, strontium ranelate, growth factors, anti-sclerostin antibodies, bisphosphonates, selective estrogen receptors, RANK ligand inhibitors; or b) anti-bacterial substances, antibiotics, halogen-releasing compounds, peroxides, biguanides, chlorhexidine; or c) metals, silver, zinc, and copper compounds. |
| Claim: | 4. The composition according to claim 1 , wherein the mineral particles are: calcium phosphates selected from the group consisting of calcium pyrophosphate, calcium carbonate, monocalcium phosphate monohydrate, monocalcium phosphate, anhydrous dicalcium phosphate, dicalcium phosphate dihydrate, octocalcium phosphate, alpha-tricalcium phosphate, beta-tricalcium phosphate, hydroxy-apatite, tetracalcium phosphate, calcium-deficient hydroxyapatite, fluoroapatite, amorphous calcium phosphate oxyapatite; Ca-containing bioactive silica glasses and P-containing bioactive silica glasses. |
| Claim: | 5. The composition according to claim 1 , wherein the cross-linked hydrogel chunks have a mean diameter from 50 to 500 μm. |
| Claim: | 6. The composition according to claim 1 , wherein the hydrogel of the cross-linked hydrogel chucks is a polymeric material selected from the group consisting of polysaccharides, hyaluronic acid and derivatives thereof, heparin, heparan sulfate, chondroitin sulfate, dermatan sulfate, keratin sulfate, chitin, chitosan, agarose, agar, collagen, gelatin, elastin and fibrin. |
| Claim: | 7. The composition according to claim 1 , wherein the mineral particles are in a shape of needles. |
| Claim: | 8. The composition according to claim 1 , wherein a ratio of the first phase to the second phase in terms of volume is in a range of 3:1 to 19:1. |
| Claim: | 9. The composition according to claim 1 , wherein the composition is essentially free of a hyaluronidase inhibitor. |
| Claim: | 10. The composition according to claim 3 , wherein the mineral particles are loaded with a bisphosphonate. |
| Claim: | 11. The composition according to claim 1 , wherein the mineral particles have a mean diameter of from 50 nm to 5 μm. |
| Claim: | 12. A method for repairing bone defects and augmenting fragile bone structures comprising injecting the composition according to claim 1 into a bone defect or a fragile bone structure. |
| Claim: | 13. A method for treating periodontitis and peri-implantitis-related bone defects or for bone augmentation comprising injecting the composition according to claim 1 into a bone. |
| Claim: | 14. A method for treating periodontal or peri-implant bone defects comprising applying the composition according to claim 1 to a bone. |
| Claim: | 15. A method for minimally-invasive application of the composition according to claim 1 to superficial periodontal or peri-implant bone defects, the method comprising steps: a) cleaning by extensive scaling and root planning of an affected tooth/implant to remove all infected tissues and any plaque/biofilm on a surface of the tooth/implant; and b) applying the composition via subgingival injection from a syringe directly into the bone defect. |
| Claim: | 16. The method according to claim 15 , wherein the cleaning done during step a) is done mechanically, by means of light, ultrasound, with a water-jet or with an air-jet. |
| Claim: | 17. A method for minimally-invasive application of the composition according to claim 1 for a sinus lift, comprising the steps: a) gaining access to a site to be treated by creating a gingival flap; b) creating a small opening to a sinus cavity by means of drilling or punching; c) elevating a Schneiderian membrane; and d) filling a void in an upper jaw area via an injection of the composition through the small opening created in step b). |
| Claim: | 18. A method for minimally-invasive application of the composition according to claim 1 for bone augmentation in orthopedics, comprising the steps: a) gaining access to a targeted bone via a very small soft tissue incision or purposefully sized cannula or trocar; b) creating an opening of less than 1 mm in a cortex of the targeted bone by means of drilling or punching; c) applying the composition via an injection from a syringe into trabecular bone; and d) closing the soft tissues. |
| Patent References Cited: | 4673355 June 1987 Farris 8790681 July 2014 Altschuler 20060257492 November 2006 Wen 20130224277 August 2013 Amedee 2014169236 October 2014 |
| Other References: | Fujishiro et al (J Chem Tech Biotechnol, 1993, 57, 349-353). (Year: 1993). cited by examiner Kattimani et al (Bone and Tissue Regeneration Insights, 2016:7, 9-19). (Year: 2016). cited by examiner Hulsart-Billström, Gry et al., “Morphological differences in BMP-2-induced ectopic bone between solid and crushed hyaluronan hydrogel templates,” Journal of Materials Science: Materials in Medicine, 2013, p. 1201-1209, vol. 24 No. 5, Springer Science+Business Media, USA. cited by applicant Hulsart-Billström, Gry et al., “Calcium phosphates compounds in conjunction with hydrogel as carrier for BMP-2: A study of ectopic bone formation in rats,” Acta Biomaterialia, Aug. 2011, p. 3042-3049, vol. 7 No. 8, Elsevier Ltd., The Netherlands. cited by applicant Fricain, J. C. et al. “A nano-hydroxyapatite—Pullulan/dextran polysaccharide composite macroporous material for bone tissue engineering” Biomaterials, 2013, pp. 2947-2959, vol. 34. cited by applicant |
| Primary Examiner: | Roney, Celeste A |
| Attorney, Agent or Firm: | Saliwanchik, Lloyd & Eisenschenk |
| رقم الانضمام: | edspgr.11577005 |
| قاعدة البيانات: | USPTO Patent Grants |
كن أول من يترك تعليقا!